During the past decade, LKH Leoben conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 5 clinical trials were completed, i.e. on average, 41.7% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 4 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "LKH Leoben" #1 sponsor was "Celgene" with 4 trials, followed by "Arbeitsgemeinschaft medikamentoese Tumortherapie" with 3 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored, "Alliance Foundation Trials, LLC." with 1 trials sponsored and "Amgen" with 1 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "LKH Leoben" #1 collaborator was "Amgen" with 2 trials as a collaborator, "Austrian Breast & Colorectal Cancer Study Group" with 2 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "Medical University of Vienna" with 2 trials as a collaborator and "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 1 trials as a collaborator. Other collaborators include 43 different institutions and companies that were collaborators in the rest 53 trials.

According to Clinical.Site data, the most researched conditions in "LKH Leoben" are "Multiple Myeloma" (5 trials), "Breast Cancer" (2 trials), "Metastatic Breast Cancer" (2 trials), "Acute Myeloid Leukemia" (1 trials) and "Advanced Breast Cancer" (1 trials). Many other conditions were trialed in "LKH Leoben" in a lesser frequency.

Most popular intervention types in "LKH Leoben" are "Drug" (18 trials), "Procedure" (3 trials), "Biological" (2 trials), "Other" (2 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Lenalidomide" (2 trials), "radiation therapy" (2 trials), "5-Fluoruracil, Cisplatinum" (1 trials) and "Abraxane" (1 trials). Other intervention names were less common.

The vast majority of trials in "LKH Leoben" are 23 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "LKH Leoben". undefined are not yet recruiting, 6 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in LKH Leoben, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in LKH Leoben, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".

LKH Leoben has several departments that took part in Clinical trials: "LKH Leoben, Abt. für Innere Medizin" - 5 trials, "LKH Hochsteiermark - Leoben, Abt. f. Innere Medizin, Haemato-Onkologie" - 2 trials